Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 7/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7738139 | 0.87 | NPC1 (0.41) | RAB9ANPC1KDM4EPPARGPPARA | |
| SCHEMBL11006922 | 0.81 | KDM4E (0.67) | RAB9ANPC1KDM4EPPARGPPARA | |
| SCHEMBL5845568 | 0.80 | PPARG (0.51) | RAB9ANPC1KDM4EPPARGPPARA | |
| SCHEMBL4748511 | 0.80 | PPARG (0.54) | PPARGPPARAFFAR1PPARD | |
| SCHEMBL979145 | 0.80 | KDM4E (0.65) | RAB9ANPC1KDM4EPPARGPPARA | |
| SCHEMBL4414123 | 0.79 | KDM4E (0.47) | RAB9ANPC1KDM4EPPARGPPARA | |
| SCHEMBL4744513 | 0.77 | KDR (0.66) | PPARGPPARAKDR | |
| SCHEMBL4888378 | 0.77 | RAB9A (0.62) | RAB9ANPC1KDM4EPPARGPPARA | |
| SCHEMBL6603331 | 0.77 | PPARA (0.47) | RAB9ANPC1KDM4EPPARGPPARA | |
| SCHEMBL8135402 | 0.76 | KDM4E (0.50) | NPC1KDM4EPPARGPPARAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1227231-C | Ether and amide compounds as medicide for treating glycuresis and preparing process thereof | KOTOBUKI SEIYAKU CO LTD (JP) | 2005-11-16 | — | — | CN | disclosed |
| US-6414001-B2 | Ether and amide compounds preparation thereof composition containing same and use thereof as antidiadetics | KOTOBUKI PHARMACEUTICAL CO. LTD. (JP) | 2002-07-02 | — | — | US | disclosed |
| US-20010008898-A1 | Ether and amide compounds and preparation of thereof as antidiadetics. | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2001-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008898-A1 | Ether and amide compounds and preparation of thereof as antidiadetics. | SLC5A2, GCG, NCEH1 | RAB9A 1873/4885NPC1 721/4885KDM4E 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.